C. non-albicans

Introduction. More attention is drawn to Candida spp. blood infections and its frequency especially in the development of intervention treatment technologies and the increasfng number of immunosuppressive patients. Our aim was to de­termine the Candida species, clinical in­dicators, patient outcomes and to identify risk factors interfaces in C. albicans and C. non-albicans for patients with candidemia, who were treated in inten­sive care unit (ICU) and those who had not been treated in ICU.